Tula, Tula, Russian Federation
Tula, Russian Federation
Tula, Russian Federation
Tula, Tula, Russian Federation
Saharnyy diabet 2 tipa — shiroko rasprostranennoe bystro progressiruyuschee zabolevanie, harakterizuyuscheesya razvitiem sosudistyh izmeneniy, privodyaschih v snizheniyu kachestva zhizni pacientov, k invalidizacii i povysheniyu smertnosti ot serdechno-sosudistyh oslozhneniy. Saharnyy diabet 2 tipa chasto voznikaet v sostave metabolicheskogo sindroma, kotoryy ob'edinyaet mnozhestvennye obmennye narusheniya s harakternymi patologicheskimi izmeneniyami organov, v chastnosti razvitiem steatogepatita (nealkogol'noy zhirovoy bolezni pecheni). Pri vyrazhennyh patologicheskih sdvigah v pokazatelyah transaminaz i sostoyanii giperglikemii, edinstvennym saharosnizhayuschim preparatom yavlyalsya insulin. Vvedenie insulina pacientu s morbidnym ozhireniem, s sindromom giperinsulinizma za schet povyshennoy endogennoy produkcii insulina v usloviyah insulinorezistentnosti — redko pozvolyaet dostigat' celevyh pokazateley uglevodnogo obmena, no chasto provociruet nezhelatel'nye effekty, takie kak pribavka massy tela, skrytye gipoglikemicheskie sostoyaniya i t. d. Odnim iz osnovnyh napravleniy nauchnyh issledovaniy v diabetologii yavlyaetsya poisk saharosnizhayuschih preparatov s maksimal'noy effektivnost'yu i minimal'nymi pobochnymi effektami, takimi kak uvelichenie massy tela i gipoglikemicheskie sostoyaniya. Odnim iz takih sredstv yavlyaetsya: preparat gruppy ingibitorov natriy-glyukoznogo kotransportera 2 tipa (iSGLT-2) dapagliflozin. Dapagliflozin (Forsiga) byl pervym predstavitelem novogo klassa peroral'nyh saharosnizhayuschih preparatov iSGLT-2, odobrennym k primeneniyu v RF. Nastoyaschaya stat'ya obobschaet regional'nyy opyt primeneniya dapagliflozina v endokrinologicheskom otdelenii TOKB №2 im. L. N. Tolstogo u pacientov s saharnym diabetom 2 tipa i s nealkogol'noy zhirovoy bolezn'yu pecheni. Na konkretnyh klinicheskih primerah pokazana vozmozhnost' primeneniya dapagliflozina kak al'ternativu insulinu u pacientov s saharnym diabetom 2 tipa s nealkogol'noy zhirovoy bolezn'yu pecheni.
saharnyy diabet 2tipa, dapagliflozin, kardiobezopasnost', gipoglikemicheskie sostoyaniya, nealkogol'naya zhirovaya bolezn' pecheni, serdechno-sosudistye oslozhneniya
1. IDF Diabetes Atlas. 7th ed. Brussels: International Diabetes Federation, 2015
2. Anciferov M. B., Fadeev V. V., Morgunova T. B. Sovremennye podhody k lecheniyu pacientov s saharnym diabetom 2 tipa // Farmateka. 2016. №16 (329). S. 50-55.
3. Schernthaner G. Diabetes and cardiovascular disease: is intensive glucose control beneficial or deadly? Lessons from aCCORD, aDVaNCE, VaDT, UKPDS, PROactive and NICE-SUGaR. Wien Med. Wochenschr. 2010; 160: 8-19.
4. Schernthaner G. H., Schernthaner G. Insulin resistance and inflammation in the early phase of type 2 diabetes: potential for therapeutic intervention. Scand. J. Clin. Lab. Invest. 2005; 240(Suppl.): 30-40
5. Forsiga (dapagliflozin). Registracionnoe udostoverenie // htp://grls.rosminzdrav.ru/Grls_View_v2.aspx?idReg=434071&t=
6. Instrukciya po medicinskomu primeneniyu lekarstvennogo preparata Forsiga (tabletki, pokrytye plenochnoy obolochkoy, 5 mg, 10 mg) s uchetom izmeneniy 1, 2. Registracionnoe udostoverenie LP-002596 ot 21/08/2014.
7. Algoritmy specializirovannoy medicinskoy pomoschi bol'nym saharnym diabetom / Pod red. I. I. Dedova, M. V. Shestakovoy (8-y vypusk). - M.: UPPRINT; 2017. 112 s. DOIhttps://doi.org/10.14341/DM20171S8
8. Michael A. Weber, Traci A. Mansfield, Federica Alessi et al. Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade // Blood Pressure. Vol. 25. Iss. 2. 2016. P. 93-103 doihttps://doi.org/10.3109/08037051.2015.1116258
9. Paola Fioretto, Angelo Avogaro. Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes // Expert Opinion On Pharmacotherapy. Vol. 18. Iss. 5. 2017. P. 517-527.
10. Karpov Yu. A., Shubina A. T. Korrekciya faktorov serdechno-sosudistogo riska: novye perspektivy saharosnizhayuschey terapii // Atmosfera. Novosti kardiologii. 2016. №2. S. 26-32.
11. Ob utverzhdenii perechney zhiznenno neobhodimyh i vazhneyshih lekarstvennyh preparatov dlya medicinskogo primeneniya na 2017 god. Rasporyazhenie ot 28 dekabrya 2016 goda. № 2885-r // http://government.ru/docs/25924/
